Monograph

N05AD01 - Haloperidol

Propably not porphyrinogenic

Rationale

No data pointing to CYP-induction. Repeatedly used in acute porphyria without ill effects. Several references state non-porphyrinogenicity.

Chemical description

Butyrphenone low-dose neuroleptic used in psychotic conditions (e.g.in paranoia), also in childhood. Used in confusion states in elderly and against vomiting, e.g. in radiation sickness. Extensively metabolized, CYPs probably involved. No data pointing to CYP-inducing properties. Australian list: safe (conflicting evidence) EPI-list: safe South African list: use French list: use Martindale: Haloperidol is considered to be safe in patients with porphyria although there is conflicting experimental evidence of porphyrinogenicity.

IPNet drug reports

Uneventful use reported in 3 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes N05A / N05AD or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames